Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP lifted its position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 191.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 124,571 shares of the company's stock after purchasing an additional 81,757 shares during the quarter. Marshall Wace LLP owned 0.64% of Nuvectis Pharma worth $674,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nations Financial Group Inc. IA ADV lifted its stake in shares of Nuvectis Pharma by 35.0% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company's stock valued at $73,000 after buying an additional 3,500 shares in the last quarter. Baxter Bros Inc. boosted its stake in Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock worth $81,000 after buying an additional 2,500 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Nuvectis Pharma in the 4th quarter valued at about $135,000. Forbes J M & Co. LLP increased its stake in shares of Nuvectis Pharma by 21.9% in the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company's stock worth $319,000 after buying an additional 10,599 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock valued at $501,000 after purchasing an additional 26,489 shares during the period. 96.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NVCT shares. HC Wainwright restated a "buy" rating and issued a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th. Laidlaw started coverage on shares of Nuvectis Pharma in a report on Monday, March 17th. They issued a "buy" rating and a $19.00 target price for the company. Finally, Maxim Group began coverage on Nuvectis Pharma in a report on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 price target on the stock.

Nuvectis Pharma Price Performance

NASDAQ NVCT traded down $0.18 on Wednesday, hitting $8.78. The stock had a trading volume of 140,823 shares, compared to its average volume of 126,672. The stock has a market cap of $207.36 million, a price-to-earnings ratio of -7.57 and a beta of -0.11. The business's fifty day moving average price is $8.83 and its 200 day moving average price is $7.20. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. As a group, sell-side analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Insider Buying and Selling at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 240,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the transaction, the insider now owns 2,884,121 shares of the company's stock, valued at $14,420,605. The trade was a 9.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 35.78% of the stock is owned by corporate insiders.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.